Manal Mohamed Makhlouf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manal Mohamed Makhlouf has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Nihal Salah Ibrahim
Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications- Zainab Ali El-Saadany
Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications - Samah Abd Elhamid
Clinical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications Abeya A Lotfi
Department of Electron Microscopy; Theodor Bilharz Research Institute; Giza; Egypt
1 shared publicationAlaa Amr Gad
Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo - Egypt
1 shared publication- Alaa Khalil Kamel
Human Cytogenetics Department, National Research Centre, Dokki, Egypt
1 shared publication
Latest Publications
- 28 April 2026
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 35 (1) , 57
Association of CD247 rs858554 polymorphism with immune thrombocytopenia susceptibility and treatment response in Egyptian children
- 28 April 2026
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 35 (1) , 57
Association of CD247 rs858554 polymorphism with immune thrombocytopenia susceptibility and treatment response in Egyptian children
- 10 January 2025
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 34 (1) , 133-142
Exploring abnormal hemostatic parameters and coagulopathy in a cohort of Egyptian patients with COVID-19 disease
- 10 January 2025
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 34 (1) , 133-142
Exploring abnormal hemostatic parameters and coagulopathy in a cohort of Egyptian patients with COVID-19 disease
- 22 September 2022
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 128, 104834
The impact of MCP1-2518A/G and CCR2-V64I genetic polymorphisms in Egyptian sickle cell disease patients
- 22 September 2022
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 128, 104834
The impact of MCP1-2518A/G and CCR2-V64I genetic polymorphisms in Egyptian sickle cell disease patients
- Open Access
- 6 August 2022
- Published by Springer Nature in Journal of Hematopathology
- Vol. 15 (3) , 131-140
The risk and prognostic influence of caspase 9 promotor polymorphisms in Egyptian patients with acute myeloid leukemia
Acute myeloid leukemia (AML) is a genetic disorder of hematopoietic stem cells (HSCs) followed by clonal selection and uncontrolled proliferation leading to malignant neoplasm. Inappropriate regulation of apoptosis contributes to many human disorders including cancer. Caspase 9 (CASP9) is associated with the intrinsic pathway of apoptosis. Functional single-nucleotide polymorphisms (SNPs) in CASP9 might influence gene expression leading to altered apoptosis and increased AML risk. Previously, two CASP9 promoter polymorphisms (CASP9 1263 rs4645978A > G and CASP9 712 rs4645981C > T) were shown to be associated with increased risk of developing AML and inferior AML survival in South Indian subjects. This study was to evaluate these polymorphisms in an independent cohort of AML patients and controls in Egypt. PCR–RFLP for CASP9 1263 rs4645978 A > G and CASP9 712 rs4645981 C > T genotypes were done in 60 de novo AML cases and 40 healthy control subjects. Our study showed that CASP9 712 rs4645981 C > T gene polymorphism is associated with increased risk of developing AML and poor disease outcome (p value = 0.006, < 0.001; OR = 3.644, 26; and 95% CI = 1.39–9.528, 6.5–103.5, respectively). In contrast, CASP9 1263 rs4645978 A > G showed no significant difference between AML patients and the controls regarding the risk of developing AML or disease outcome (p value = 0.301, 0.573, respectively). CASP9 712 rs4645981 C > T could be involved in the pathophysiology and development of AML in Egypt and may be useful as a predictive molecular markers for inferior prognosis in AML. Notably, risk was highest and outcomes worst in patients with both the 712C > T and 1263A > G alleles.
- 6 August 2022
- Published by Springer Nature in Journal of Hematopathology
- Vol. 15 (3) , 131-140
Open AccessThe risk and prognostic influence of caspase 9 promotor polymorphisms in Egyptian patients with acute myeloid leukemia
Acute myeloid leukemia (AML) is a genetic disorder of hematopoietic stem cells (HSCs) followed by clonal selection and uncontrolled proliferation leading to malignant neoplasm. Inappropriate regulation of apoptosis contributes to many human disorders including cancer. Caspase 9 (CASP9) is associated with the intrinsic pathway of apoptosis. Functional single-nucleotide polymorphisms (SNPs) in CASP9 might influence gene expression leading to altered apoptosis and increased AML risk. Previously, two CASP9 promoter polymorphisms (CASP9 1263 rs4645978A > G and CASP9 712 rs4645981C > T) were shown to be associated with increased risk of developing AML and inferior AML survival in South Indian subjects. This study was to evaluate these polymorphisms in an independent cohort of AML patients and controls in Egypt. PCR–RFLP for CASP9 1263 rs4645978 A > G and CASP9 712 rs4645981 C > T genotypes were done in 60 de novo AML cases and 40 healthy control subjects. Our study showed that CASP9 712 rs4645981 C > T gene polymorphism is associated with increased risk of developing AML and poor disease outcome (p value = 0.006, < 0.001; OR = 3.644, 26; and 95% CI = 1.39–9.528, 6.5–103.5, respectively). In contrast, CASP9 1263 rs4645978 A > G showed no significant difference between AML patients and the controls regarding the risk of developing AML or disease outcome (p value = 0.301, 0.573, respectively). CASP9 712 rs4645981 C > T could be involved in the pathophysiology and development of AML in Egypt and may be useful as a predictive molecular markers for inferior prognosis in AML. Notably, risk was highest and outcomes worst in patients with both the 712C > T and 1263A > G alleles.
- 30 December 2020
- Published by S. Karger AG in Pathobiology
- Vol. 88 (3) , 211-217
CXC Chemokine Receptor Type 5 Gene Polymorphisms in a Cohort of Egyptian Patients with Diffuse Large B-Cell Lymphoma
Background: The chemokine receptor CXCR5 is selectively expressed on B cells; it is involved in lymphocyte homing and the development of normal lymphoid tissue. Its principle ligand is CXCL13 or B lymphocyte chemoattractant. Three polymorphisms in the CXCR5 gene, rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A, have been identified. Objective: To assess the genetic polymorphisms of CXCR5 and evaluate their possible contribution to the susceptibility and response to therapy of diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Fifty DLBCL (not otherwise specified) patients and 50 control subjects were included in this study. CXCR5 genotypes were determined by PCR-RFLP. Results: Our study revealed that the CXCR5 rs148351692 C/G and rs6421571 C/T gene polymorphisms are associated with an increased risk of developing DLBCL (OR 28.57 [95% CI 8.96–96.56] and 3.45 [1.67–11.83] respectively), while CXCR5 rs78440425 G/A showed no association with the risk of lymphoma. Moreover, the double and triple combined gene polymorphisms are associated with an increased risk of developing DLBCL of approximately 120-fold and 105-fold, respectively. CXCR5 gene polymorphisms had no significant impact on disease outcome or response to therapy. Conclusions: CXCR5 gene polymorphisms could be considered a potential risk factor for the development of DLBCL.
- 30 December 2020
- Published by S. Karger AG in Pathobiology
- Vol. 88 (3) , 211-217
CXC Chemokine Receptor Type 5 Gene Polymorphisms in a Cohort of Egyptian Patients with Diffuse Large B-Cell Lymphoma
Background: The chemokine receptor CXCR5 is selectively expressed on B cells; it is involved in lymphocyte homing and the development of normal lymphoid tissue. Its principle ligand is CXCL13 or B lymphocyte chemoattractant. Three polymorphisms in the CXCR5 gene, rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A, have been identified. Objective: To assess the genetic polymorphisms of CXCR5 and evaluate their possible contribution to the susceptibility and response to therapy of diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Fifty DLBCL (not otherwise specified) patients and 50 control subjects were included in this study. CXCR5 genotypes were determined by PCR-RFLP. Results: Our study revealed that the CXCR5 rs148351692 C/G and rs6421571 C/T gene polymorphisms are associated with an increased risk of developing DLBCL (OR 28.57 [95% CI 8.96–96.56] and 3.45 [1.67–11.83] respectively), while CXCR5 rs78440425 G/A showed no association with the risk of lymphoma. Moreover, the double and triple combined gene polymorphisms are associated with an increased risk of developing DLBCL of approximately 120-fold and 105-fold, respectively. CXCR5 gene polymorphisms had no significant impact on disease outcome or response to therapy. Conclusions: CXCR5 gene polymorphisms could be considered a potential risk factor for the development of DLBCL.
- 1 May 2020
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 32 (5) , 616-622
Influence of esophageal variceal bleeding on iron status in chronic hepatitis C patients
Background: Disorders of serum iron balance are frequently observed in chronic hepatitis C (CHC) patients. Iron overload as well as iron deficiency anemia are common clinical findings in these patients. Variceal bleeding is also a common complication. To date, no study has discussed the influence of esophageal bleeding on iron status in anemic CHC bleeders. Objective: Was to study reticulocyte hemoglobin content (CHr) and serum hepcidin levels in anemic CHC and to evaluate the influence of variceal bleeding on patients’ iron status. Methods: Serum hepcidin levels and CHr were assessed in 65 early phase CHC patients (20 nonanemic, 23 anemic nonbleeders, and 22 anemic bleeders), and 20 healthy controls; and were compared with the conventional indices of iron deficiency including mean corpuscular volume, mean corpuscular hemoglobin, red cell distribution width, serum iron, total iron binding capacity, transferrin saturation and ferritin. Results: Hepcidin levels were comparable in patients groups, but were significantly lower in patients than in controls (P = 0.01). Child-Pugh class B patients showed significantly lower hepcidin levels than class A patients. CHr levels were comparable in all groups as well as all iron deficiency indices. Patients with ferritin values or less 100 ng/ml and CHr or less 29 pg/cell or Tfsat or less 16% are more likely to have iron deficiency [odds ratio (OR = 3.93, 95% confidence interval (CI) = 2.54–6.08; OR = 10.50, 95% CI = 1.94–56.55, respectively). Conclusion: Esophageal bleeding has an almost no influence on iron status in CHC patients. Serum hepcidin content is influenced by CHC disease rather than by anemia associated with or without esophageal bleeding and it could be used as a marker of early hepatic insufficiency. Assessing CHr content could add a potential utility in the detection of iron deficiency in CHC patients.
- 1 May 2020
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 32 (5) , 616-622
Influence of esophageal variceal bleeding on iron status in chronic hepatitis C patients
Background: Disorders of serum iron balance are frequently observed in chronic hepatitis C (CHC) patients. Iron overload as well as iron deficiency anemia are common clinical findings in these patients. Variceal bleeding is also a common complication. To date, no study has discussed the influence of esophageal bleeding on iron status in anemic CHC bleeders. Objective: Was to study reticulocyte hemoglobin content (CHr) and serum hepcidin levels in anemic CHC and to evaluate the influence of variceal bleeding on patients’ iron status. Methods: Serum hepcidin levels and CHr were assessed in 65 early phase CHC patients (20 nonanemic, 23 anemic nonbleeders, and 22 anemic bleeders), and 20 healthy controls; and were compared with the conventional indices of iron deficiency including mean corpuscular volume, mean corpuscular hemoglobin, red cell distribution width, serum iron, total iron binding capacity, transferrin saturation and ferritin. Results: Hepcidin levels were comparable in patients groups, but were significantly lower in patients than in controls (P = 0.01). Child-Pugh class B patients showed significantly lower hepcidin levels than class A patients. CHr levels were comparable in all groups as well as all iron deficiency indices. Patients with ferritin values or less 100 ng/ml and CHr or less 29 pg/cell or Tfsat or less 16% are more likely to have iron deficiency [odds ratio (OR = 3.93, 95% confidence interval (CI) = 2.54–6.08; OR = 10.50, 95% CI = 1.94–56.55, respectively). Conclusion: Esophageal bleeding has an almost no influence on iron status in CHC patients. Serum hepcidin content is influenced by CHC disease rather than by anemia associated with or without esophageal bleeding and it could be used as a marker of early hepatic insufficiency. Assessing CHr content could add a potential utility in the detection of iron deficiency in CHC patients.
- Open Access
- 1 October 2017
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 50 (5) , 565-569
Molecular and serological assessment of parvovirus B-19 infection in Egyptian children with sickle cell disease
- 1 October 2017
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 50 (5) , 565-569
Open AccessMolecular and serological assessment of parvovirus B-19 infection in Egyptian children with sickle cell disease
- 19 April 2016
- Published by SAGE Publications in Tumori Journal
- Vol. 103 (3) , 268-271
TAp73 and ΔNp73 Relative Expression in Egyptian Patients with Lymphoid Neoplasms
Background and aims: The p73 gene has different isoforms with opposing anti- and pro-apoptotic functions. The pro-apoptotic activities are inhibited by overexpression of the dominant ΔNp73 isoform. The aim of this study was to detect the expression of the TAp73 and ΔNp73 isoforms in Egyptian patients with malignant lymphoid neoplasms. Their expression was analyzed by quantitative RT-PCR. Patients and Methods: The study included 30 B-NHL patients, 24 T-NHL patients, 16 ALL patients, 18 CLL patients, 22 patients with reactive lymphoid hyperplasia, and 6 healthy control subjects. Results: ALL and CLL patients expressed both isoforms at higher levels compared to lymphoma patients. Higher expression of TAp73 was found in both B-NHL and T-NHL (around 4-fold and 16-fold, respectively) in comparison to ΔNp73 (2-fold and 14-fold, respectively). In CLL patients both isoforms showed higher expression levels in comparison to normal peripheral blood lymphocytes controls: nearly 27-fold for TAp73 and 233-fold for ΔNp73. All ALL patients showed higher expression of both studied isoforms than controls (9-fold for TAp73 and 386-fold for ΔNp73). The highest ΔNp73 expression along with a higher ΔNp73/TAp73 ratio (67-fold) was found in ALL patients compared with CLL patients (21-fold). Conclusions: A considerable number of lymphoma patients lacked the expression of either or both isoforms, while all lymphoid leukemia patients expressed both isoforms. The expression pattern differences of p73 isoforms may reflect differences in the biology of these malignancies.
- 19 April 2016
- Published by SAGE Publications in Tumori Journal
- Vol. 103 (3) , 268-271
TAp73 and ΔNp73 Relative Expression in Egyptian Patients with Lymphoid Neoplasms
Background and aims: The p73 gene has different isoforms with opposing anti- and pro-apoptotic functions. The pro-apoptotic activities are inhibited by overexpression of the dominant ΔNp73 isoform. The aim of this study was to detect the expression of the TAp73 and ΔNp73 isoforms in Egyptian patients with malignant lymphoid neoplasms. Their expression was analyzed by quantitative RT-PCR. Patients and Methods: The study included 30 B-NHL patients, 24 T-NHL patients, 16 ALL patients, 18 CLL patients, 22 patients with reactive lymphoid hyperplasia, and 6 healthy control subjects. Results: ALL and CLL patients expressed both isoforms at higher levels compared to lymphoma patients. Higher expression of TAp73 was found in both B-NHL and T-NHL (around 4-fold and 16-fold, respectively) in comparison to ΔNp73 (2-fold and 14-fold, respectively). In CLL patients both isoforms showed higher expression levels in comparison to normal peripheral blood lymphocytes controls: nearly 27-fold for TAp73 and 233-fold for ΔNp73. All ALL patients showed higher expression of both studied isoforms than controls (9-fold for TAp73 and 386-fold for ΔNp73). The highest ΔNp73 expression along with a higher ΔNp73/TAp73 ratio (67-fold) was found in ALL patients compared with CLL patients (21-fold). Conclusions: A considerable number of lymphoma patients lacked the expression of either or both isoforms, while all lymphoid leukemia patients expressed both isoforms. The expression pattern differences of p73 isoforms may reflect differences in the biology of these malignancies.
- 17 March 2016
- Published by Taylor & Francis in Biomarkers
- Vol. 21 (5) , 416-423
The clinical relevance and prognostic significance of microsomal epoxide hydrolase gene polymorphisms and their susceptibility to acquired aplastic anemia: an Egyptian study
Microsomal epoxide hydrolase enzyme (mEPHX) is involved in xenobiotics detoxification. Two variants of mEPHX, Tyr113His and His139Arg, have been described. Both may lead to acquired aplastic anemia (AA).
- 17 March 2016
- Published by Taylor & Francis in Biomarkers
- Vol. 21 (5) , 416-423
The clinical relevance and prognostic significance of microsomal epoxide hydrolase gene polymorphisms and their susceptibility to acquired aplastic anemia: an Egyptian study
Microsomal epoxide hydrolase enzyme (mEPHX) is involved in xenobiotics detoxification. Two variants of mEPHX, Tyr113His and His139Arg, have been described. Both may lead to acquired aplastic anemia (AA).
- 18 February 2016
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 20 (2) , 151-159
Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients
Introduction Hemophilias are a group of related bleeding disorders that show an X-linked pattern of inheritance. The clinical phenotype of severe hemophilia may vary markedly among patients as a result of many factors, including genetic prothrombotic risk factors. Objectives Our objective was to study the incidence of the most common prothrombotic risk factors for additive effects among Egyptian patients with hemophilia A and their impact on clinical phenotype; annual bleeding frequency and severity of hemophilic arthropathy, as well as the effect of a single variation in these patients. Methods This study was carried out in 100 patients with hemophilia A. Genotyping for factor V Leiden (FVL) G1691A, prothrombin G20210A, MTHFR C677T, and A1298C mutations was conducted using a real time-polymerase chain reaction (RT-PCR) assay. Results Our study revealed mutations in hemophilia patients as follows: prothrombin G20210A (3 %), FVL (14 %), MTHFR C677T (42 %), and A1298C (59 %). Despite a lack of statistical significance when each gene was analysed separately, heterozygosity of prothrombin G20210A or FVL was always associated with either a mild or moderate, but never a severe, clinical presentation. The lowest bleeding frequency (less than once per month) was identified among patients with two heterozygous variants irrespective of the involved genes. In addition, the incidence of hemarthrosis was significantly higher among patients with a wild genotype of the prothrombin gene and FVL, and the average number of affected joints was significantly higher among patients with wild-type prothrombin and FVL genes than among heterozygous patients. Conclusion These prothrombotic mutations have a cumulative effect in amelioration of the severity of bleeding in hemophiliacs. The most prominent effect is that of prothrombin G20210A and FVL, while MTHFR C677A and A1298C gene mutations are less conclusive.
- 18 February 2016
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 20 (2) , 151-159
Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients
Introduction Hemophilias are a group of related bleeding disorders that show an X-linked pattern of inheritance. The clinical phenotype of severe hemophilia may vary markedly among patients as a result of many factors, including genetic prothrombotic risk factors. Objectives Our objective was to study the incidence of the most common prothrombotic risk factors for additive effects among Egyptian patients with hemophilia A and their impact on clinical phenotype; annual bleeding frequency and severity of hemophilic arthropathy, as well as the effect of a single variation in these patients. Methods This study was carried out in 100 patients with hemophilia A. Genotyping for factor V Leiden (FVL) G1691A, prothrombin G20210A, MTHFR C677T, and A1298C mutations was conducted using a real time-polymerase chain reaction (RT-PCR) assay. Results Our study revealed mutations in hemophilia patients as follows: prothrombin G20210A (3 %), FVL (14 %), MTHFR C677T (42 %), and A1298C (59 %). Despite a lack of statistical significance when each gene was analysed separately, heterozygosity of prothrombin G20210A or FVL was always associated with either a mild or moderate, but never a severe, clinical presentation. The lowest bleeding frequency (less than once per month) was identified among patients with two heterozygous variants irrespective of the involved genes. In addition, the incidence of hemarthrosis was significantly higher among patients with a wild genotype of the prothrombin gene and FVL, and the average number of affected joints was significantly higher among patients with wild-type prothrombin and FVL genes than among heterozygous patients. Conclusion These prothrombotic mutations have a cumulative effect in amelioration of the severity of bleeding in hemophiliacs. The most prominent effect is that of prothrombin G20210A and FVL, while MTHFR C677A and A1298C gene mutations are less conclusive.